Pain is one of the most debilitating symptoms that presents with neuropathy. Neuropathic pain syndrome is a challenge to treat and, even with appropriate evidence-based treatment, only a 40% ...
The manufacturer of AV-101, an investigational, oral nonopioid, NMDA-targeting therapy to treat neuropathic pain, announced that it has received a U.S. patent for the treatment. AV-101 (4-Cl-KYN) is ...
Simran Gill is a PhD student in the Pharmacology and Physiology program. She is working on a project ... Jagger worked on a project investigating the role of glutamate transporters in neuropathic pain ...
The disciplines of pharmacology and physiology touch on virtually every field of the ... “Investigating cannabinoid combinations in the treatment of chronic neuropathic pain and alcohol use disorder.” ...
Vistagen (VTGN) announced that the U.S. Patent and Trademark Office or USPTO, granted a patent to the company for its oral non-opioid product ...
The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...
Hosted on MSN1mon
Treating Your Depression and Nerve Pain With CymbaltaNerve pain — a side effect of HIV medications ... To understand how Cymbalta works, you must first understand the physiology of depression. Two naturally occurring chemicals in the brain ...
Study shows AP-325 offers lasting pain relief without central side effects Algiax Pharmaceuticals, a company committed to developing innovative treatments for chronic neuropathic pain, has released ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback